Evaluation of CSF [cerebrospinal fluid] levels of Tarceva (OSI-774) [erlotinib] in patients with stage III non-small cell lung cancer and no CNS involvement undergoing treatment with Tarceva.
Phase of Trial: Phase I
Latest Information Update: 16 May 2011
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 27 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
- 10 Oct 2006 New trial record.